Benzinga | Jun 18, 2021 01:27PM EDT

Roche's New COVID-19 Point Of Care Test Scores FDA Emergency Use Nod

* The FDA has granted Emergency Use Authorization (EUA) to Roche Holding AG's (OTC:RHHBY) Cobas SARS-CoV-2 Nucleic acid test for use on the Cobas Liat System.

* This singleplex test is the first real-time RT-PCR test to identify SARS-CoV-2 infection within 20 minutes, both asymptomatic and symptomatic persons.

* The test will be available in July.

* Price Action: RHHBY shares down 0.75% at $47.14 during the market trading session on the last check Friday.